Immutep (Nasdaq:IMMP) - Stock Price, News & Analysis

Resumen acción IMMP

Immutep Limited, empresa biotecnológica en fase clínica, se dedica al desarrollo de la nueva inmunoterapia LAG-3 para el cáncer y las enfermedades autoinmunes.

Acerca de la empresa

IMMP fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Cotiza un 94.7% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los beneficios de 56.99%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

No tiene ingresos significativos (A$4M)

Competidores de Immutep Limited

Inovio Pharmaceuticals

NasdaqCM:INO

US$257.8m

Enanta Pharmaceuticals

NasdaqGS:ENTA

US$348.0m

2seventy bio

NasdaqGS:TSVT

US$258.6m

Pyxis Oncology

NasdaqGS:PYXS

US$286.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Immutep
Historical stock prices
Current Share Price	AU$2.49
52 Week High	AU$3.90
52 Week Low	AU$1.50
Beta	1.83
1 Month Change	4.18%
3 Month Change	-3.49%
1 Year Change	56.60%
3 Year Change	-24.32%
5 Year Change	31.05%
Change since IPO	-93.80%

Noticias y actualizaciones recientes

Recent updates

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Oct 04

Immutep secures €1.8M cash in French government's research tax credit

Sep 23

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Aug 30

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Jul 06

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Jun 12

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Mar 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Jun 21

Immutep to enroll additional patients in mid-stage study with its lead cancer program

Nov 19

Immutep rallies on Australian patent grant for IMP701 antibody

Nov 09

Rentabilidad de los accionistas

	IMMP	US Biotechs	Mercado US
7D	-11.1%	-2.8%	-1.7%
1Y	56.6%	-0.2%	22.4%

Rentabilidad vs. Industria: IMMP superó al sector US Biotechs , que obtuvo un rendimiento del 5.8% el año pasado.

Rentabilidad vs. Mercado: IMMP superó al mercado US, que obtuvo un rendimiento del 22.3% el año pasado.

Volatilidad de los precios

Is IMMP's price volatile compared to industry and market?
IMMP volatility
IMMP Average Weekly Movement	7.9%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: IMMP no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de IMMP (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1987	n/a	Marc Voigt	www.immutep.com

Immutep Limited, empresa biotecnológica en fase clínica, se dedica al desarrollo de la nueva inmunoterapia LAG-3 para el cáncer y las enfermedades autoinmunes. La empresa se dedica a desarrollar terapias relacionadas con el gen de activación linfocitaria 3 (LAG-3), una molécula de la superficie celular que desempeña un papel vital en la regulación del sistema inmunitario. Sus inmunoterapias LAG-3 están diseñadas para aprovechar y reforzar el poder del sistema inmunitario de los pacientes en la lucha contra el cáncer y las enfermedades autoinmunes.

Resumen de fundamentos de Immutep Limited

¿Cómo se comparan los beneficios e ingresos de Immutep con su capitalización de mercado?
Estadísticas fundamentales de IMMP
Capitalización bursátil	US$287.94m
Beneficios(TTM)	-US$26.16m
Ingresos (TTM)	US$2.54m

113.4x

Ratio precio-ventas (PS)

-11.0x

Ratio precio-beneficio (PE)

¿Está IMMP sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de IMMP
Ingresos	AU$3.93m
Coste de los ingresos	AU$37.72m
Beneficio bruto	-AU$33.79m
Otros gastos	AU$6.71m
Beneficios	-AU$40.50m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.034
Margen bruto	-859.57%
Margen de beneficio neto	-1,030.32%
Ratio deuda/patrimonio	0.8%

¿Cómo se ha desempeñado IMMP a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción IMMP

Recompensas

Análisis de riesgos

Competidores de Immutep Limited

NasdaqCM:INO

US$257.8m

NasdaqGS:ENTA

US$348.0m

NasdaqGS:TSVT

US$258.6m

NasdaqGS:PYXS

US$286.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Recent updates

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Immutep secures €1.8M cash in French government's research tax credit

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Immutep Limited Appoints Lucy Turnbull as Non-Executive Director

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022

Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha

Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study

Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates

Immutep Receives FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC

Immutep Limited Signs Agreement to Commence New Phase I Trial, Called Insight-003, to Evaluate the Combination of Lead Product Candidate Eftilagimod Alpha

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Immutep Limited Reveals a New anti-LAG-3 Research Program

Immutep reveals anti-LAG-3 research program

Immutep Limited Reports Positive Data from Its Tacti-002 Phase Ii Study of Lag-3 Therapy, Efti, At Asco 2021

Immutep Limited Reports Positive Final Data from Insight-004 Trial